

CURRICULUM VITAE FOR:
Janelle Boger Perkins, Pharm.D, BCOP

Current Position: Associate Professor
Department of Pharmacotherapeutics and Clinical Research
College of Pharmacy
University of South Florida
12901 Bruce B. Downs Blvd.
Tampa, Florida 33612
Phone: 813-974-6237
Fax: 813-905-9778
email: jperkin1@health.usf.edu

Associate Professor
Department of Oncologic Sciences
College of Medicine
University of South Florida

Education:

1984 Bachelor of Science in Pharmacy with High Honors, University of Florida,
College of Pharmacy
1986 Doctorate of Pharmacy, University of North Carolina School of Pharmacy

Postgraduate Training and Fellowship Appointments:

1984 Pharmacy Internship at the VA Medical Center in Gainesville, Florida
1986-87 Residency in Oncology Pharmacy Practice at Audie Murphy VA Hospital and
University of Texas Health Sciences Center in San Antonio

Academic Appointments and Employment:

1984 Staff Pharmacist, The Prescription Shop, Stuart, Florida
1985 Externship Teaching Assistant, School of Pharmacy, University of North
Carolina, Chapel Hill
1987-1989 Clinical Pharmacist in Hematology/Oncology, H. Lee Moffitt Cancer Center &
Research Institute, Tampa, Florida
1987-2000 Clinical Assistant Professor, College of Pharmacy, University of Florida,
Gainesville, Florida

1989-1992	Clinical Pharmacist in Bone Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
1992-1994	Associate in Research, Division of Bone Marrow Transplantation, Department of Internal Medicine, College of Medicine, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, Florida
1994-2006	Manager, BMT Clinical Research, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, Florida
1994-2010	Assistant Professor, Division of Bone Marrow Transplantation, Department of Internal Medicine/Interdisciplinary Oncology/Oncologic Sciences; College of Medicine
2008-2010	Assistant Member; Department of Blood and Marrow Transplantation; Moffitt Cancer Center
2010-2013	Associate Member; Department of Blood and Marrow Transplantation; Moffitt Cancer Center and Associate Professor; Department of Oncologic Sciences; College of Medicine
2013-Present	Associate Professor; Department of Pharmacotherapeutics and Clinical Research; College of Pharmacy and Associate Professor; Department of Oncologic Sciences; College of Medicine; University of South Florida; Director, Clinical Investigational Research Pharmacy

Licenses

State of Florida (PS0020873) - Active
State of North Carolina (8896) - Inactive

Board Certifications

Pharmacotherapy, 1993-2008
Oncology Pharmacotherapy, 2008-present

Teaching Experience

1986-1987	Clinical Instructor, PharmD Curriculum Clinical Pharmacy Programs, University of Texas, San Antonio
1987-2002	Preceptor, Clinical Pharmacy Clerkship for PharmD candidates; University of Florida College of Pharmacy
1992-Present	Preceptor, Oncology Pharmacy Practice Residency, Department of Pharmacy H. Lee Moffitt Cancer Center & Research Institute
1997	Lecturer, Medical Oncology Fellows Lecture Series in Clinical Pharmacology of Chemotherapy; H. Lee Moffitt Cancer Center & Research Institute
1999-2003	Lecturer, Working Professional Doctor of Pharmacy Program; University of Florida College of Pharmacy
1999-2002	Lecturer, Pharmacotherapy III course; PharmD Curriculum University of Florida College of Pharmacy
2007-present	Lecturer; BMT Grand Rounds, Moffitt Cancer Center
2008-2011	Lecturer, Interdisciplinary Oncology Clerkship for 4 th year University of South Florida Medical Students (BCC 8117)
2012-present	Lecturer; BMT Lecture Series

2013	Lecturer; Clinical Pharmacokinetics and Pharmacodynamics (PHA 6129); College of Pharmacy; University of South Florida
2013	Lecturer; Introduction to Health Professions (IDS 2931); College of Art and Sciences; University of South Florida
2013	Lecturer; Drug Delivery Systems II (PHA 6115); College of Pharmacy; University of South Florida
2013	Co-coordinator and lecturer for Pharmacotherapeutics III (PHA 6784C); College of Pharmacy; University of South Florida
2013	Coordinator and lecturer for Research Methods and Biostatistics (PHA 6795); College of Pharmacy; University of South Florida
2014	Coordinator and lecturer for Clinical Pharmacokinetics and Pharmacodynamics (PHA 6129); College of Pharmacy; University of South Florida

Honors and Awards

Roche Pharmacy Communications Award, 1984
Rho Chi National Honor Society
Graduation with High Honors, University of Florida, 1984
Sandoz Outstanding Doctor of Pharmacy Student, 1986

Service:

University Of South Florida

1999-2001 Publications Council
2000-Present Institutional Review Board
2009-Present Chairperson
2013 Chair, Promotion Task Force
Department of Pharmacotherapeutics and Clinical Research
2013 Participation in Pre-Health Summer Enrichment Program (PSEP)

H. Lee Moffitt Cancer Center & Research Institute

2003-2013 Scientific Review Committee
2003 Clinical Research Office Policy and Procedures Development Committee
2005-2006 BMT Performance Improvement Committee
2005, 2007 BMT Survivor Reunion Planning Committee
2008-2013 BMT Clinical Standards Committee

Professional

1995-2001 Editorial Board, Journal of Oncology Pharmacy Practice
1992-1995 Residency Advisory Council, Oncology Pharmacy Practice Residency
Department of Pharmacy, H. Lee Moffitt Cancer Center & Research Institute,
Tampa, Florida
2009-present Reviewer, Pharmacotherapy Self-Assessment Program
2011-present Reviewer, ACCP/ASHP Oncology Pharmacy Preparatory Review Course
2011 Ad hoc reviewer, *Bone Marrow Transplantation*
2011 Ad hoc reviewer, *Leukemia Research*
2012 Reviewer, Fundamentals in Hematopoietic Cell Transplantation Course

Community

2005-Present Youth Worker; Bells Shoals Baptist Church; Brandon, Florida

- 2009 Planning Committee Member, Bloomingdale Relay for Life, American Cancer Society
2013 Participation in USF College of Pharmacy Upward Bound Program

Professional Association Memberships:

- 1992-Present Southwest Florida Society of Health-System Pharmacists
1992-Present Florida Society of Health-System Pharmacists,
1992-1994 Clinical Affairs Council
1992-Present American College of Clinical Pharmacy
1992-1994 Committee on Clinical Practice Affairs
2009-2011 Committee on Research Affairs
2011-2012 Practice-Based Research Network Community Advisory Panel
2012 PRN Frontiers Fund Captain
2012 Hematology/Oncology PRN Programming Committee
1994-Present American Society of Health-System Pharmacists
1994-Present American Society of Clinical Oncology
2003-2010 Association of Clinical Research Professionals
2007-Present American Society of Blood and Marrow Transplantation
2012 BMT Pharmacy SIG Steering Committee
2011-Present American Society of Hematology
2011-Present Hematology Oncology Pharmacy Association
2012 Annual Meeting Research Abstract Review Workgroup
2013 BCOP Recertification Committee

Peer Reviewed Publications

Boger JJ (maiden name), Araujo OE, and Flowers FP. Sunscreens: Efficacy, Use and Misuse. South Med J 77:421-27, 1984.

Perkins JB and Raasch RH. Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever. Drug Intell Clin Pharm 21:343-5, 1987.

Perkins JB. Gynecologic Malignancies: Detection, prevention, and therapeutics. American Pharmacy NS28 (11&12):718-21, 778-81; 1988.

Fields K, Elfenbein G, Saleh R, Zorsky P, Janssen W, **Perkins J**, Saleh T, Piazza J, Kronish L, Machak M, Lyman G. Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: Focus on breast cancer and lymphoma. Hematol Oncol 10:61-74, 1992.

Burnette PK and **Perkins JB**. Parenteral Ondansetron for the Treatment of Chemotherapy and Radiation Induced Nausea and Vomiting. Pharmacotherapy 12: 120-131, 1992.

Fields KK, **Perkins JP**, Hiemenz JW, Zorsky PE, Janssen WE, Kronish LE, Machak MC, and Elfenbein GJ. Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a Phase I/II study in breast cancer patients. Surg Oncol 2:87-95, 1993

Zorsky PE, **Perkins JB**. Optimizing high dose therapy using pharmacokinetic principles. Semin Oncol 20(suppl 6):2-18, 1993

- Fields KK, Elfenbein GJ, **Perkins JB**, Hiemenz JW, Janssen WE, Zorsky PE, Ballester OF, Kronish LE, Foody MC. Two novel high dose treatment regimens for metastatic breast cancer: ifosfamide, carboplatin plus etoposide (ICE) and mitoxantrone plus thiotepa (MITT): Outcomes and toxicities. *Semin Oncol* 20(suppl 6):59-66, 1993.
- Benson K, Fields K, Hiemenz J, Zorsky P, Ballester O, **Perkins J**, Elfenbein G. The platelet refractory bone marrow transplant patient: Prophylaxis and treatment of bleeding. *Semin Oncol* 20 (suppl 6):102-109, 1993.
- Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, **Perkins JB**, Creger RJ, Ballester OF, Hiemenz JW, Janssen WE, Zorsky PE. Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autologous stem cell rescue: Toxicity profile. *J Clin Oncol*; 13:323-332, 1995.
- Fields KK, Elfenbein GJ, Trudeau WL, **Perkins JB**, Moscinski LC. The clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high dose chemotherapy and autologous bone marrow transplantation. *J Clin Oncol*; 14:6, 1868-76, 1996.
- Perkins JB**, Fields KK, Elfenbein GJ. Ifosfamide/Carboplatin/Etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation evaluation of dose response relationships. *Semin Oncol* 22(suppl 7):5-8, 1995.
- Fields KK, **Perkins JB** and Elfenbein GJ, Reply to Letter-to-the-Editor. *J Clin Oncol* 13:1826-1827, 1995
- Perkins JB**, Elfenbein GJ, Fields KK. Analysis of dose response relationships in the setting of high dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: Implications for the treatment of patients with advanced breast cancer. *Semin Oncol* 23 (suppl 6):42-46, 1996.
- Fields KK, Partyka JS, **Perkins JB**, Elfenbein GJ. Optimization of High Dose Therapy for the Treatment of Patients with Metastatic Breast Cancer. *J Oncol Pharm Practice* 2:11-17, 1996.
- Ballester OF, Agalotis DP, Hiemenz JW, Janssen WE, Fields KK, Zorsky PE, Goldstein SC, **Perkins JB** and Elfenbein. Phase I-II study of high dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: Toxicities and hematopoietic recovery. *Bone Marrow Transplant* 18: 9-14, 1996.
- Fields KK, **Perkins JB**, Partyka JS, and Elfenbein GJ. High-dose therapy for the treatment of patients with breast cancer: Evaluation of effect of regimen on outcome. *Bone Marrow Transplant* 18(suppl 1):s30-s33, 1996
- Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, **Perkins JB**, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. *Bone Marrow Transplant* 20: 653-656, 1997.

- Agaliotis DP, Ballester OF, Mattos T, Heimenz JW, Fields DD, Zorsky PE, Goldstein SC, **Perkins JB**, Rosen RM, and Elfenbein GJ. Nephrotoxicity of high dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation. *Am J Med Sci* 314:292-298, 1997.
- Fields KK, Elfenbein GJ, **Perkins JB**, et al. Defining the role of novel high dose chemotherapy regimens for the treatment of high risk breast cancer. *Semin Oncol* 25: (2 suppl 4): 1-6, 1998.
- Ayala E, Greene J, Sandin R, **Perkins J**, Field T, Tate C, Fields KK, Goldstein S. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation*. 2006;37:851-856.
- Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, **Perkins J**, Fernandez H, Perez L, Ayala E, Anasetti C. Infliximab for managing steroid-refractory acute graft-versus-host disease.. *Biol Blood Marrow Transplant*. 2009;15:1116-1121
- Field T, **Perkins J**, Huang Y, Kharfan-Dabaja M, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacytidine for Myelodysplasia before Allogeneic Hematopoietic Cell Transplantation. *Bone Marrow Transplant*. 2010;45:255-260.
- Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell M, Huang Y, Anasetti C, and **Perkins J**. Voriconazole Provides Effective Prophylaxis for Invasive Fungal Infection in Patients Receiving Glucocorticoid Therapy for Graft-Versus-Host Disease. *Bone Marrow Transplant*. 2010; 45:662-667.
- Pidala J, Kharfan-Dabaja M, Kim J, **J Perkins**, Field T, Perez L, Ayala E, Ochoa-Bayona L, Raychaudhuri J, Fernandez H, Anasetti C. Mycophenolate mofetil for the management of steroid-refractory acute graft vs. host disease: A single center analysis of patient outcomes. *Bone Marrow Transplant*. 2010; 45:919-924.
- Hoda D, Pidala J, Salgado-Vila N, Kim J, **Perkins J**, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. *Bone Marrow Transplant*. 2010 ;45:1347-1351.
- Perkins J**, Anasetti C, Ayala E, Fernandez H, Kharfan-Dabaja M, Perez L, Kim J, Field T. Comparing the Safety of Tacrolimus And Methotrexate (MTX) Versus Tacrolimus And Mycophenolate Mofetil (MMF) As Graft Versus Host Disease Prophylaxis In Allogeneic Hematopoietic Cell Transplants (HCT). *Biol Blood Marrow Transplant*. 2010;16:937-947.
- Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, **Perkins J**, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. *J Hematol Oncol*. 2010;3:36
- Nishihori T, **Perkins J**, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Reduced Toxicity Conditioning and Allogeneic

- Hematopoietic Cell Transplantation for Myelofibrosis: A Single-Center Experience. *Am J Hematol.* 2010;85:904-907
- Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, **Perkins J**, Perez L, Fernandez H, Anasetti C. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. *Biol Blood Marrow Transplant.* 2011;17:239-248.
- Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, **Perkins J**, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. *Biol Blood Marrow Transplant.* 2011;17:384-393.
- Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, **Perkins J**, Ayala E, Perez L, Fernandez H. Targeted Intravenous Busulfan and Fludarabine (t-IV Bu/Flu) Provides Effective Control of Acute Myelogenous Leukemia in Adults with Reduced Toxicity. *Bone Marrow Transplant.* 2011;46:641-649.
- Perkins J**, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner J, Miller S, and Anasetti C. Pharmacokinetic Targeting of Intravenous Busulfan Combined with Fludarabine (FluBu) as Conditioning Prior to Hematopoietic Cell Transplant Neutralizes the Effects of First Dose Exposure on Transplant-Related Morbidity and Mortality. *Bone Marrow Transplant.* 2011;46:1418-1425.
- Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, **Perkins J**, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2011;17:1237-1244.
- Pidala J, Roman-Diaz J, Kim J, Nishihori T, **Perkins J**, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. *Int J Hematol.* 2011;93:206-12.
- Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, **Perkins J**, Raychaudhuri J, Fernandez H, Anasetti C. Fludarabine and Pharmacokinetic-Targeted Busulfan Before Allografting for Adults with Acute Lymphoid Leukemia. *Biol Blood Marrow Transplant.* 2011;17:1505-1511.
- Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, **Perkins J**, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. *Haematologica.* 2011;96:1351-1356.
- Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, **Perkins J**. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus

criteria, is associated with overall survival and non-relapse mortality. *Haematologica*. 2011;96:1678-1684.

Perkins JB, Goldstein SC, Dawson JL, Kim J, Field TL, Partyka JS, Fields KK, Maddox BL, Simonelli CE, Neuger AM, Lush RM, Sullivan DM. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. *Clin Cancer Res*. 2011;17:7743-7753.

Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2011 Dec 23. [Epub ahead of print]

Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, **Perkins J**, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. *Haematologica*. 2012 Dec;97(12):1882-9. doi: 10.3324/haematol.2012.067140. Epub 2012 Jun 11.

Perkins JB, Shapiro JF, Bookout RN, Yee GC, Anasetti C, Janssen WE, and Fernandez HF. Retrospective Comparison of Filgrastim plus Plerixafor to Other Regimens for Remobilization after Primary Mobilization Failure: Clinical and Economic Outcomes. *Am J Hematol*. 2012 Jul;87(7):673-7. doi: 10.1002/ajh.23221. Epub 2012 Jun 3.

Kharfan-Dabaja MA, Anasetti C, Fernandez HF, **Perkins J**, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II Study of CD4(+)-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. *Biol Blood Marrow Transplant*. 2013 Jul;19(7):1087-93. doi: 10.1016/j.bbmt.2013.04.020. Epub 2013 Apr 28.

Duong VH, Lancet JE, Alrawi E, Al-Ali NH, **Perkins J**, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. *Leuk Res*. 2013 May;37(5):510-5. doi: 10.1016/j.leukres.2012.12.012. Epub 2013 Jan 16

Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, **Perkins J**, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. *Bone Marrow Transplant*. 2013 Mar;48(3):346-50. doi: 10.1038/bmt.2012.150. Epub 2012 Aug 6.

Kunter G, **Perkins J**, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona L, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted busulfan and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first remission. *Bone Marrow Transplant*, In press

Invited Publications/Non Peer Reviewed Publications

Perkins JB, Scott J, Terpin J, and Grimes S. The role of the pharmacist in cancer therapy. *American Druggist* 20(3):40-46, 1990.

Perkins JB and Yee GC. High-dose chemotherapy and bone marrow transplantation. *J Pharm Pract* 4:20-26; 1991.

Perkins JB. Update on hematopoietic growth factors. *P & T*. Vol 19 (6), 573:86. June 1994.

Perkins J and Partyka J. Update on interleukins and interferons. *P & T*. Vol 19 (12), 1128:37. December 1994.

Anasetti C, Perkins J, Nieder M, Field T. Are matched unrelated donor transplants justified for AML in CR1? *Best Practice & Research Clinical Hematology* 19:321-328, 2006.

Perkins JB. Pomalidomide-Drug Update; Hematology/Oncology Pharmacy Association Newsletter 10: 17-19, 2013

Book Chapters

Perkins JB, Buffington D, Hoffman M. Gynecologic Malignancies. In: *Pharmacotherapy: A Pathophysiologic Approach* (DiPiro JT, Talbert RL, Hayes PE, Yee GC and Posey LM, Eds.) 2nd Edition. 1992.

Fields KK, Elfenbein GJ, **Perkins JB**, Ballester OF, Hiemenz JW, Zorsky PE. Event-free survival in breast cancer patients treated with high-dose ifosfamide, carboplatin, and etoposide and autologous stem cell rescue: Analysis of risk factors. In: Einhorn J, Nord CE, Norrby SR, eds. *Recent Advances in Chemotherapy*. Washington DC: American Society of Microbiology, 1993: 974-5.

Janssen WE, Smilee R, Carter R, Rahn D, Cairo M, Hiemenz JW, Zorsky PE, Fields KK, Ballester O, **Perkins J**, Kronish L, Elfenbein GJ. Mobilization of peripheral blood stem cells (PBSC): Comparing cyclophosphamide and growth factor based regimens. In: *Advances in Bone Marrow Purging and Processing*. (Worthington-White D, Gee A, Gross S, Eds.) Wiley-Liss, New York, pp. 429-439, 1994.

Fields KK, Elfenbein GJ, **Perkins JB**, Ballester OF, Hiemenz JW, and Zorsky PE. Event-free survival in breast cancer patients treated with high dose ifosfamide, carboplatin and etoposide and autologous stem cell rescue: Analysis of risk factors. In: *Recent Advances in Chemotherapy, Proceedings of the 18th International Congress of Chemotherapy*. (Einhorn L, Nord C, and Norrby S, eds). Washington, DC, pp 974-975, 1994

Fields KK, Elfenbein GJ, **Perkins JB**, Moscinski L. High dose versus standard dose chemotherapy for the treatment of breast cancer: A review of current concepts. In *Annals of the New York Academy of Sciences* (Sackstein R, Janssen WE, Elfenbein GJ, eds), New York, NY, pp.288-304, 1995.

Fields K, Partyka J, Elfenbein G, Trudeau W, Kronish L, **Perkins J**, and Moscinski L. Minimal residual disease in the bone marrow of patients with breast cancer under going bone marrow transplant: Prognostic significance. In: *Autologous Blood and Marrow Transplantation, Proceedings of the 8th International Symposium*. (Dicke DA, Keating A, eds) Carden Jennings, Charlottesville, VA, pp305-312, 1997.

- Elfenbein GJ, Janssen WE, **Perkins JB**, Partyka JS, and Fields KK. Mathematical modeling of human hematopoiesis: Lessons learned from the bedside following autologous peripheral blood stem cell transplants. In: Autologous Blood and Marrow Transplantation, Proceedings of the 8th International Symposium. (Dicke DA, Keating A, eds) Carden Jennings, Charlottesville, VA, pp 443-466, 1997
- Perkins JB**, Fields KK, Partyka JS, and Elfenbein GJ. Novel high dose regimens for the treatment of breast cancer. In: Autologous Blood and Marrow Transplantation, Proceedings of the 8th International Symposium. (Dicke DA, Keating A, eds) Carden Jennings, Charlottesville, VA, pp 387-394, 1997.
- Perkins JB**. Major Histocompatibility complex. In: Concepts in Immunology and Immunotherapeutics. 3rd edition., 1997.
- Fields KK, **Perkins JB**, Elfenbein GJ, Goldstein SC, Sullivan DM, Partyka JS, Trudeau WL. Evaluation of Prognostic Factors for Patients With Breast Cancer Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant: A Single Institution Experience. In: Autologous Blood and Marrow Transplantation: Proceedings of the Ninth International Symposium. (Dicke KA, Keating A, eds) Carden Jennings, Charlottesville, VA, pp 341-352, 1999.
- Janssen WE, Elfenbein GJ, **Perkins JB**, Partyka JS, Smilee RC, Ballester OF, Goldstein SC, Fields KK, Hiemenz JW, Sackstein R, Zorsky PE. Final Report of the First Prospective, Stratified, Randomized Trial Comparing G-CSF-Primed Bone Marrow Cells With G-CSF-Mobilized Peripheral Blood Cells for Pace of Hematopoietic Engraftment and Disease-Free Survival after High-Dose Therapy and Autotransplant. In: Autologous Blood and Marrow Transplantation: Proceedings of the Ninth International Symposium. (Dicke KA, Keating A, eds) Carden Jennings, Charlottesville, VA, pp 580-598, 1999.
- Perkins JB** and Yee GC. Bone Marrow Transplantation. In: Pharmacotherapy: A Pathophysiologic Approach, 4th ed. (Dipiro Jt, Talbert JL, Yee GC, Matzke GR, Wells BG, and Posey LM, eds). Appleton and Lange, Stamford, CT, pp 2195-2220, 1999
- Fields, KK., **Perkins, JB.**, Goldstein, S., Sullivan, D., Field, T., Djulbegovic, B., and Partyka, J. High Dose Thiotepa, Mitoxantrone, and Paclitaxel Followed by Peripheral Blood Stem . Publication in Autologous Blood and Marrow ,Volume X. In Press, 2000.
- Perkins JB** and Yee GC. Blood and Marrow Transplantation. In: Pharmacotherapy: A Pathophysiologic Approach, 5th ed. (Dipiro JT, Talbert JL, Yee GC, Matzke GR, Wells BG, and Posey LM, eds). Appleton and Lange, Stamford, CT, 2002
- Perkins JB** and Yee GC. Hematopoietic Stem Cell Transplantation. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, and Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach, 6th ed. New York, McGraw Hill, 2005: 2541-2558.
- Perkins JB** and Yee GC. Hematopoietic Stem Cell Transplantation. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, and Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach, 7th ed. New York, McGraw Hill, 2008: 2331-2347.
- Perkins JB** and Yee GC. Hematopoietic Stem Cell Transplantation. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, and Posey LM, eds. Pharmacotherapy: A Pathophysiologic

Approach, 8th ed. New York, McGraw Hill, 2011: 2455-2472.

Scientific Abstracts/Poster Presentations

- Fields KK, Elfenbein GJ, Saleh RA, Janssen WE, Saleh TG, **Perkins JB**, and Kronish LE. Ifosfamide, Carboplatin, and Etoposide (ICE) Combination Chemotherapy in Refractory, Metastatic Breast Cancer -- Preliminary Results. 13th Annual San Antonio Breast Cancer Symposium. Breast Cancer Research & Treatment 16:133, 1990
- Fields KK, Saleh RA, Janssen WE, Saleh TG, **Perkins JB**, Kronish LE, Elfenbein GJ. Ifosfamide, carboplatin and etoposide (ICE) combination chemotherapy in refractory lymphoma ---preliminary results. Blood 76(suppl 1):348a, 1990.
- Fields K, Elfenbein G, Zorsky P, Saleh R, Janssen W, **Perkins J**, Saleh T, Piazza J, Kronish L, Machak M. a two day regimen of ifosfamide, carboplatin and etoposide (mini-ICE) for breast cancer and lymphomas. Presented at Florida Division American Cancer Society, Orlando, March, 1991.
- Fields K, Elfenbein G, Zorsky P, Saleh R, Janssen W, **Perkins J**, Saleh T, Piazza J, Kronish L, Machak M. High dose ifosfamide, carboplatin and etoposide (ICE) regimen followed by autologous BMT for breast cancer, lymphomas, and other malignancies. Presented at Florida Division American Cancer Society, Orlando, March, 1991.
- Zorsky P, Greene J, **Perkins J**, Elfenbein G, Fields K, Saleh R, Janssen W, Piazza J, Saleh T, Kronish L, Machak M. Toxicity and efficacy comparison of aerosolized pentamidine versus trimethoprim-sulfamethoxazole (TMP/SMX) for pneumocystis carinii pneumonia prophylaxis in bone marrow transplantation patients. Presented at Florida Division American Cancer Society, Orlando, March, 1991.
- Fields KK, Zorsky PE, Saleh RA, **Perkins JB**, Saleh TG, Kronish LE, Machak MK, Elfenbein GJ. A Phase I-II Study of High-Dose Ifosfamide, Carboplatin and Etoposide (ICE) with Autologous Bone Marrow Rescue (ABMR): Preliminary Results. Proc. ASCO 10:70, 1991.
- Fields KK, Zorsky PE, Saleh RA, **Perkins JB**, Saleh TG, Kronish LE, Machak MK, Elfenbein GJ. Treatment of Refractory Metastatic Breast Cancer with Ifosfamide, Carboplatin, and Etoposide (ICE). Proc. ASCO 10:70, 1991.
- Fields KK, Zorsky PE, Saleh RA, **Perkins JB**, Saleh TG, Kronish LE, Machak MK, Elfenbein GJ. A Phase I-II Study of High-Dose Ifosfamide, Carboplatin, and Etoposide (ICE) and Autologous Bone Marrow Rescue (ABMR): Toxicity (TOX). Proc. ASCO 10:121, 1991.
- Elfenbein G, Fields K, Janssen W, Zorsky P, Saleh R, **Perkins J**. Rapid Platelet Recovery after High Dose Ifosfamide, Carboplatin, and Etoposide (ICE) Followed by Autologous (AUTO) BMT. Exp Hematol 19:557, 1991.
- Greene J, Yangco B, Chmel H, Solomon D, **Perkins J**, Elfenbein G. Comparative Evaluation of Aerosolized Pentamidine versus Trimethoprim-Sulfamethoxazole for Pneumocystis Carinii Pneumonia Prophylaxis in Bone Marrow Transplant Patients. Presented at the 17th International Congress of Chemotherapy, Berlin, Germany, June, 1991.
- Benson K, Fields K, Zorsky P, **Perkins J**, Elfenbein G. Aminocaproic Acid (EACA) to Control Severe Bleeding in Bone Marrow Transplant (BMT) Recipients. Blood 78 (suppl 1):475a (Abstract #1890), 1991.

- Fields KK, Elfenbein GJ, Zorsky PE, **Perkins JB**, Gonzalez JP, Kronish LE, Craig J, Pach M, Machak MC. Preliminary Results of High-Dose Ifosfamide, Carboplatin, and Etoposide (ICE) with Autologous Bone Marrow Rescue (ABMR) for the Treatment of Breast Cancer (CA). *Breast Cancer Research & Treatment* 19:171, 1991 (Abstract #54).
- Fields K, Zorsky P, **Perkins J**, Gonzalez J, Green S, Oelslager P, Kronish L, Machak M, Elfenbein G. Ifosfamide, carboplatin and etoposide (ICE) in the treatment of refractory lymphoma. *Blood* 78 (suppl 1):117a (Abstract #459), 1991.
- Fields KK, Elfenbein GJ, Zorsky PE, Hiemenz JW, Saleh RA, Cooper BW, **Perkins JB**, Kronish LE, Machak MC. Ifosfamide, carboplatin and etoposide (ICE) with autologous stem cell rescue (ASCR): Phase I results. *J Cell Biochem Suppl* 16A:202, 1992.
- Elfenbein G, Fields K, Zorsky P, Hiemenz J, Janssen W, **Perkins J**, Gonzalez J, Green S, Oelslager P, Kronish L, Machak M. Ifosfamide, carboplatin and etoposide (ICE) with autologous stem cell rescue (ASCR): Toxicities. *Proc. ASCO* 11:90, 1992.
- Fields K, Zorsky P, Hiemenz J, **Perkins J**, Gonzalez J, Green S, Oelslager P, Kronish L, Machak M, Elfenbein G. Ifosfamide, carboplatin and etoposide (ICE) in the treatment of refractory malignancy. *Proc. ASCO*, 11:90, 1992.
- Fields K, Elfenbein G, Hiemenz J, Zorsky P, **Perkins J**, Gonzalez J, Green S, Oelslager P, Kronish L, Holcomb D, Machak M, Sullivan P, Pach L. High-dose thiotepa and mitoxantrone (MITT) followed by autologous stem cell rescue (ASCR) for refractory cancer. *Exp. Hematol.* 20:714, 1992.
- Greene J, Yangco B, Chmel H, Solomon D, Elfenbein G, **Perkins J**, Hiemenz J. Toxicity of aerosolized pentamidine vs trimethoprim sulfamethoxazole for prevention of pneumocystis pneumonia in bone marrow transplant patients. Presented at the 7th Intern. Symposium on Infections in the Immunocompromised Host, abstract #098, 1992.
- Elfenbein GJ, Fields KK, Hiemenz JW, Zorsky PE, Janssen WE, **Perkins JB**, Kronish LE, Machak MC, and Pach LD. High dose chemotherapy and autologous stem cell rescue for high risk breast cancer: results of two different regimens: one for responsive disease and one for refractory disease. 4th Annual Melanoma & Breast Cancer Conf. Orlando. Sept, 1992. Presented
- Fields KK, Elfenbein GJ, Hiemenz JW, Zorsky PE, **Perkins JB**, Kronish LE, Machak MC, and Pach LD. High-dose thiotepa and mitoxantrone with autologous stem cell reinfusion for the treatment of refractory metastatic breast cancer. *Breast Cancer Research & Treatment* 23:122, 1992.
- Agaliotis D, Janssen W, Elfenbein G, Fields K, Hiemenz J, Zorsky P, **Perkins J**. Recovery of granulopoiesis after high dose chemotherapy and autologous stem cell transplantation is dependent upon source of stem cells, use of growth factors, and treatment regimen. *Blood* 10 (suppl 1):516a, 1992.
- Fields KK, Elfenbein GJ, Hiemenz JW, Zorsky PE, **Perkins JB**, Kronish LE, Machak MC, and Pach LD. Phase I/II study of high dose thiotepa and mitoxantrone (MITT) with autologous stem cell reinfusion (ASCR) for the treatment of refractory metastatic breast cancer: Efficacy and toxicity. Sixth International Symposium on Autologous Bone Marrow Transplantation, Houston, December, 1992.

- Fields KK, Elfenbein GJ, Hiemenz JW, Zorsky PE, **Perkins JB**, Kronish LE Machak MC, Sullivan PA, Sherman MM and Pach LD. Bone marrow transplantation in the older patient: Tolerance and toxicity. Geriatric Oncology First International Conference, Buenos Aires, Argentina, October 1992.
- Fields KK, Elfenbein GJ, Hiemenz JW, Zorsky PE, **Perkins JB**, Kronish LE, Machak MC, and Pach LD. Phase I/II study of high dose thioTEPA and mitoxantrone (MITT) with autologous stem cell reinfusion (ASCR) for the treatment of refractory cancers: efficacy and toxicity. Proc ASCO 12: 97, 1993.
- Agaliotis D, Janssen W, Fields K, Hiemenz J, Zorsky P, Ballester O, **Perkins J**, and Elfenbein G. Recovery of granulopoiesis after high dose chemotherapy and autologous stem cell transplantation is dependent upon source of stem cells, use of growth factors, and treatment regimen. Accepted for presentation as a Poster at FACP, April, 1993.
- Agaliotis D, Janssen W, Fields K, Hiemenz J, Zorsky P, Ballester O, **Perkins J**, and Elfenbein G. Recovery of granulopoiesis after high dose chemotherapy and autologous stem cell transplantation is dependent upon source of stem cells, use of growth factors, and treatment regimen. Proceedings ASCO;12:1585, 1993
- Fields KK, Elfenbein GJ, **Perkins JB**, Ballester OF, Hiemenz JW and Zorsky PE. Results of phase I-II escalation trials and autologous stem cell rescue (ASCR) for the treatment of metastatic and early stage high risk breast cancer. 18th ICC Conference, Poster Presentation, Stockholm, 1993.
- Hiemenz JW, Janssen WE, Fields KK, Zorsky PE, Ballester OF, **Perkins JB**, Elfenbein GJ. Factors affecting the rate of engraftment following autologous stem cell reinfusion: Methods of peripheral blood stem cell mobilization. Exp. Hematol. 21:1164, 1993.
- Elfenbein GJ, Janssen WE, Hiemenz JW, Fields KK, Zorsky PE, Ballester OF, **Perkins JB**. Factors affecting the rate of engraftment following autologous stem cell rescue: Conditioning regimen. Exp. Hematol. 21:1164, 1993.
- Agaliotis DP, Fields KK, Ballester OF, Hiemenz JW, Zorsky PE, Janssen WE, **Perkins JB**, Pach LD, Elfenbein GJ. Event free survival in patients with metastatic breast cancer undergoing high dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Exp. Hematol. 21:1130, 1993.
- Ballester OF, Janssen WE, **Perkins JB**, Farmelo MJ, Smilee R. Serum interleukin-6 levels and marrow engraftment after high dose chemotherapy and autologous stem cell transplantation. Exp. Hematol. 21:1174, 1993.
- Fields KK, **Perkins JB**, Hiemenz JW, Janssen WE, Zorsky PE, Ballester OF, Elfenbein GJ. Results of two high dose regimens with autologous stem cell transplant for metastatic breast cancer: 1) Ifosfamide, carboplatin, and etoposide and 2) Mitoxantrone and thiotepa. Breast Cancer Res and Treat. 27:183, 1993.
- Fields KK, Elfenbein GJ, **Perkins JB**, Ballester OF, Hiemenz JW, Janssen WE, Zorsky PE. Metastatic breast cancer: Suggestion of a high dose response relationship in the setting of high dose chemotherapy and stem cell rescue. J Cell Biochem. 18B:95, 1994.
- Elfenbein G, Janssen W, Smilee R, Carter R, Rahn D, Cairo M, Hiemenz J, Zorsky P, Fields K, Ballester O, **Perkins J**, Kronish L. Mobilization of peripheral blood stem cells (PBSC): Comparing

cyclophosphamide and growth factor based regimens. J Cell Biochem. 18B:100, 1994.

Fields K, **Perkins J**, Elfenbein G, Hiemenz J, Goldstein S, Zorsky P, Kronish L, Beach B, and Galon M. Dose escalation of ifosfamide, carboplatin, and etoposide: A report of toxicity and activity in patients with refractory cancers. Proc ASCO 13:156, 1994.

Zorsky P, Fields K, Elfenbein G, **Perkins J**, Ballester O, Goldstein S, Janssen W, Hiemenz J, Kronish L, Beach B. A phase I/II study of high dose ifosfamide, carboplatin, and etoposide and autologous stem cell rescue for refractory lymphoma: Further evidence for dose intensity. Proc ASCO 13:384, 1994.

Elfenbein G, Janssen W, **Perkins J**, Hiemenz J, Ballester O, Fields K, Goldstein S, Zorsky P. Pace of engraftment following high dose chemotherapy and autologous stem cell rescue depends on stem cell priming regimen. Proc ASCO 13:440, 1994 (Accepted for platform presentation).

Agaliotis D, Ballester O, Elfenbein G, Janssen B, Fields K, Goldstein S, Hiemenz J, Zorsky P, **Perkins J**, Kronish L, Beach B. Autologous peripheral blood stem cell rescue following high dose busulfan/cyclophosphamide for the treatment of hematological malignancies is associated with rapid engraftment. Submitted to European Haematology Association, 1994.

Perkins JB, Cremers KA, Fields KK, Janssen WE, Ballester OF, Goldstein SC, Hiemenz JW, Zorsky PE, Elfenbein GJ. Differences in engraftment rate between two groups of breast cancer patients treated with the same high dose chemotherapy regimen: Potential contributing factors. Exp Hematol Vol 22(8):392a, 1994.

Elfenbein GJ, Fields KK, **Perkins JB**, Ballester OF, Goldstein SC, Hiemenz JW, and Zorsky PE. Time to relapse after high dose chemotherapy with two novel regimens for metastatic breast cancer. Exp Hematol Vol 22(8):382a, 1994.

Fields KK, Elfenbein GJ, **Perkins JP**, Ballester OF, Hiemenz JW, and Zorsky PE. Event-free survival in breast cancer patients treated with high dose ifosfamide, carboplatin, and etoposide and autologous stem cell rescue: Analysis of risk factors. Exp Hematol Vol 22(8):381a, 1994.

Fields KK, Moscinski LC, Trudeau WL, **Perkins JB**, Pach LD, and Elfenbein GJ. High incidence of bone marrow micrometastases using the polymerase chain reaction technique in patients with high risk stage II and stage III breast cancer following adjuvant therapy: Clinical correlates. Breast Cancer Res and Treat. Vol 32(suppl):139a, 1994

Fields KK, **Perkins JB**, Ballester OF, Goldstein SC, Hiemenz JW, Zorsky PE, Pach LD, and Elfenbein GJ. Time to relapse following high dose chemotherapy for the treatment of poor prognosis breast cancer: Durable remissions beyond 24 months. Breast Cancer Res and Treat Vol 32(suppl):140a, 1994.

Elfenbein GJ, **Perkins JB**, Fields KK, Ballester OF, Goldstein SC, Hiemenz JW, Janssen WE, Zorsky PE. Hematologic recovery after high dose taxol[®], novantrone[®], thiotepa (TNT) and autologous stem cell transplant: Evaluation of the effects of stem cell source and taxol[®]. Blood 10 (suppl 1):2814a, 1994.

Janssen WE, **Perkins J**, Hiemenz JW, Fields KK, Zorsky PE, Ballester OF, Goldstein SC, Smilee R, Kronish L, Elfenbein GJ. Granulocyte recovery is not different following auto-transplant with G-CSF primed bone marrow or G-CSF mobilized peripheral blood "stem cells". Blood 10 (suppl 1):367a, 1994.

- Goldstein S, Alkan S, Janssen W, Thompson J, Moscinski L, Ballester O, Hiemenz J, Zorsky P, **Perkins J**, Fields K, Elfenbein G. Chemomobilization of BCR/ABL-negative peripheral blood stem cells for autologous transplantation in chronic myelogenous leukemia. *Blood* 10 (suppl 1):2824a, 1994.
- Perkins JB**, Fields KK, Elfenbein GJ, Ballester OF, Goldstein SC, Hiemenz JW, Zorsky PE. Use of GM-CSF (leukine[®]-sargramostim) as a chemoprotectant prior to ifosfamide, carboplatin, and etoposide: Preliminary results of a randomized, controlled trial. *Blood* 10 (suppl 1):2325a, 1994.
- Fields K, **Perkins J**, Elfenbein G, Ballester O, Hiemenz J, Goldstein J, Zorsky P, and Kronish L. A phase I dose escalation trial of high dose taxol□, novantrone□, and thiotepa (TNT) followed by autologous stem cell rescue (ASCR). *Proceed ASCO*; 14:953a, 1995.
- Quilitz R, **Perkins J**, Zorsky P, Partyka J, Tate C, Elfenbein G, Fields K. The lack of effect of allopurinol on the incidence and severity of gastrointestinal complications of high dose taxol□, novantrone□, and thiotepa (TNT) followed by autologous stem cell transplantation. Poster Presentation, American College of Clinical Pharmacy Annual Meeting, Washington DC
- Janssen WE, Smilee RC, **Perkins J**, Fields KK, Hiemenz JW, Zorsky PE, Ballester OF, Goldstein SC, Kronish L, Beach B, Elfenbein GJ. Platelet and neutrophil recovery following auto-transplant with G-CSF primed marrow or G-CSF mobilized blood is not different. *Exp. Hematol.* 23:863, 1995
- Perkins JB**, Elfenbein GJ, Janssen WE, Fields KK, Ballester OF, Hiemenz JW, Zorsky PE, and Goldstein SC. Lack of difference in rate of hematopoietic recovery after bone marrow and peripheral blood stem cell infusion versus peripheral blood stem cells alone. *Exp. Hematol.* 23:761, 1995
- Fields KK, Moscinski LC, Trudeau WL, **Perkins JB**, Machesney LD, and Elfenbein GJ. Cytokeratin 19 in bone marrow detected by polymerase chain reaction predicts relapses in patients with chemoresponsive metastatic breast cancer undergoing high dose chemotherapy and autologous stem cell rescue. *Exp. Hematol.* 23:785, 1995
- Janssen WE, Smilee RC, **Perkins JB**, Fields KK, et al. Platelet and neutrophil recovery following autotransplant with G-CSF primed marrow or G-CSF mobilized blood is not different. *Exp Hematol* 23:863, 1995
- Ballester O, Zorsky P, Janssen W, Fields K, Hiemenz J, Goldstein S, **Perkins J**, Rosen R, Elfenbein G. High dose therapy with autologous peripheral blood stem cell transplantation in patients with multiple myeloma and end stage renal failure. *Blood* 86(suppl 1):206a, 1995.
- Hiemenz JW, Janssen WE, Smilee RC, **Perkins JB**, Fields KK, Ballester OF, Goldstein SC, Kronish LE, Zorsky PE, Elfenbein GJ. Neutrophil and platelet recovery following auto-transplant with G-CSF primed marrow or G-CSF mobilized blood is not different. 2nd International Symposium on Febrile Neutropenia, Abstract #26, 1995.
- Elfenbein GJ, Janssen WE, **Perkins JB**. Relative contributions of marrow microenvironment, growth factors, and stem cells to hematopoiesis in vivo in man. Review of results from autologous stem cell transplant trials and laboratory studies at the Moffitt Cancer Center. *Ann N Y Acad Sci*, 770:, 315-38; Dec 29, 1995
- Minton SE, Fields KK, Elfenbein GJ, **Perkins JB**, Machesney LD, Kronish LE. High dose taxol□,

novantrone□, and thiotepa (TNT) followed by autologous stem cell rescue (ASCR) is a very active regimen for the treatment of anthracycline refractory metastatic breast cancer. Breast Cancer Research and Treatment 37 (suppl):47, 1996.

Bazzini MD, Fields KK, Elfenbein GJ, **Perkins JB**, Kronish LE, Janssen WE. Prognostic factors predicting outcome in high risk stage II, III and inflammatory breast cancer patient undergoing high dose chemotherapy followed by autologous stem cell rescue. Breast Cancer Research and Treatment 37 (suppl):54, 1996.

Fields KK, Moscinski LC, Elfenbein GJ, Trudeau WL, Machesney LD, **Perkins JB**. Polymerase chain reaction detection of cytokeratin 19 message in bone marrows of patients with high risk breast cancer predicts relapse following bone marrow transplantation. Breast Cancer Research and Treatment 37 (suppl):66, 1996.

KK Fields, OF Ballester, SC Goldstein, JW Hiemenz, **JB Perkins**, LD Machesney, and GJ Elfenbein. Age effects in patients undergoing autologous bone marrow or peripheral blood stem cell transplantation. Proc. ASCO 15: 1621a, 1996.

JS Partyka, KK Fields, **JB Perkins**, LE Kronish, HM Lazarus, BW Cooper and GJ Elfenbein. The effects of age on tolerance of high dose ifosfamide, carboplatin and etoposide and autologous stem cell rescue: Morbidity and mortality. Proc. ASCO 15: 1622a; 1996.

Partyka JS, **Perkins JB**, Janssen WE, Ballester OF, Fields KK, Goldstein SC, Hiemenz JW, Sackstein R, Elfenbein GJ. Granulocyte and platelet recovery after autologous peripheral blood stem cell transplant (PBSCT) depends on mobilizing regimen. Blood Cell and Bone Marrow Transplants, 59 (319a); 1996.

Elfenbein GJ, **Perkins JB**, Janssen WE, Sackstein R, Partyka JS. Recovery of granulopoiesis after autologous peripheral blood stem cell transplant (PBSCT) varies with the high dose regimen (HDREG). Blood Cell and Bone Marrow Transplants, 40 (142a); 1996.

Fields KK, **Perkins JB**, Partyka JS, Elfenbein GJ. High dose chemotherapy and autologous stem cell rescue for the treatment of breast cancer -- The Tampa experience. 3rd International Symposium of High-Dose Chemotherapy and Stem Cell Transplantation in Solid Tumors, Berlin, April, 1996

Fields KK, Moscinski LC, Trudeau WL, **Perkins JB** and Elfenbein GJ. Experience with detection of minimal residual disease in autografts of patients with breast cancer undergoing high dose therapy. 3rd International Symposium on High-Dose Chemotherapy and Stem Cell Transplantation in Solid Tumors, Berlin, April, 1996.

Fields KK, Ballester OF, Goldstein SC, Hiemenz JW, **Perkins JB**, Machesney LD, Elfenbein GJ. Age effects in patients undergoing autologous bone marrow or peripheral blood stem cell transplantation. Proc ASCO 15:505, 1996.

Fields KK, Moscinski LC, Trudeau WL, **Perkins JB**, Elfenbein GJ. Incidence and clinical significance of minimal residual disease in patients with breast cancer undergoing high dose therapy and autologous bone marrow transplantation. ISHAGE: 1st International Symposium on Minimal Residual Cancer, Session IV #19, 1996

Ballester O, Sullivan P, Hendrix L, **Perkins J**, Hiemenz J, Fields K, Goldstein S, Sullivan D, Elfenbein G. Interleukin-3 is effective for engraftment failure following high-dose therapy and autologous

stem cell transplantation. Exp Hematol 24: 1104, 1996

Tummala R, Elfenbein G, Fields K, **Perkins J**, Partyka J, Kronish L. Thrombocytopenia as a complication of □ high-dose □ G-CSF used to mobilize peripheral blood stem cells. Exp Hematol 24:1104, 1996

Elfenbein G, **Perkins J**, Janssen W, Fields K. Variability in engraftment potential of different peripheral blood stem cell preparations given after cyclophosphamide, thiotepa, and carboplatin for stage II/III breast cancer. Exp Hematol 24: 1043, 1996

Fields K, Partyka J, Elfenbein G, Trudeau W, Kronish L, **Perkins J**, Moscinski L. Minimal residual disease in the bone marrow of patients with breast cancer undergoing bone marrow transplant: Prognostic significance. 8th International Symposium on Autologous Marrow and Blood Transplantation, Arlington, 1996

Perkins J, Elfenbein G, Fields K, Partyka J. Novel high dose regimens for the treatment of breast cancer. 8th International Symposium on Autologous Marrow and Blood Transplantation, Arlington, 1996

Elfenbein GJ, Janssen WE, **Perkins JB**, Partyka JS, Fields KK. Prospective, stratified, randomized, controlled trial of G-CSF stimulated bone marrow stem cells versus G-CSF mobilized peripheral blood stem cells for autologous transplantation after high dose chemotherapy. 8th International Symposium on Autologous Marrow and Blood Transplantation, Arlington, 1996

Fields KK, **Perkins JB**, Partyka JS, Elfenbein GJ. High dose therapy and autologous stem cell rescue in the treatment of breast cancer: Novel regimens. 19th Annual San Antonio Breast Cancer Symposium, San Antonio, 1996

Tummala R, Ballester O, Janssen W, Fields K, Hiemenz J, Goldstein S, **Perkins J**, Rosen R, Saez R, Elfenbein G. High dose therapy with autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal failure. 25th Annual Meeting of the International Society for Experimental Hematology, 1996

Elfenbein GJ, **Perkins JB**, Janssen WE, Partyka JS, Fields KK. Recovery of hematopoiesis after high dose therapy and autologous peripheral blood stem cell transplantation is clearly dependent upon the mobilizing regimen and the transplant regimen. Blood 10 (suppl 1): 407a, 1996.

Goldstein S, Kronish L, Ballester O, Hiemenz J, Sullivan D, Saez R, Sackstein R, Partyka J, **Perkins J**, Janssen W, Elfenbein G, Fields K. Phase I/II trial of high dose ifosfamide, carboplatin and etoposide (ICE) at maximum tolerated dosage (MTD) with autologous stem cell rescue for refractory lymphoma. Blood 10 (suppl 1): 124a, 1996.

Fields KK, **Perkins JB**, Partyka JS, Elfenbein GJ. High-dose therapy for the treatment of breast cancer: evaluation of effect of regimen on outcome. Bone Marrow Transplant 18(Suppl 1): S30-3; September 1996.

Ballester O, Saez RA, Goldstein SC, Kronish L, **Perkins J**, Elfenbein G, Hiemenz J, Sullivan D, Fields K. Autologous stem cell transplantation (ASCT) for acute leukemia prolonged event-free survival for patients in first complete remission (CR1). Proc. ASCO 16: 26a; 1997.

Singh B, Elfenbein GJ, Kronish LE, **Perkins JB**, Fields KK. Survival duration after relapse following high-dose therapy and autologous hematopoietic stem cell transplantation for high risk breast cancer

patients. Proc. ASCO 16: 117a, 1997.

Saez RA, Goldstein S, Kronish L, **Perkins J**, Partyka J, Zorsky P, Elfenbein G, Hiemenz J, Ballester O, Sullivan D, Fields K. Veno-Occlusive disease of the liver (VOD) and disease status pretransplant predict outcome in allogeneic patients (Allo-BMT) treated with cyclosporine/methotrexate (CSA/MTX) as graft-versus-host disease (GVHD) prophylaxis. Proc. ASCO 16: 125a, 1997.

Fields KK, Partyka JS, **Perkins JB**, Saez RA, Goldstein SC, Sullivan DM, Hiemenz JW, Ballester OF, Kronish LC, Elfenbein GJ. Cyclophosphamide and Taxol is an active salvage regimen in patients with anthracycline refractory metastatic breast cancer. Proc ASCO 16: 168a, 1997.

Perkins JB, Fields KK, Hiemenz JW, Goldstein SC, Ballester OF, Kronish LC, Elfenbein GJ. Clinical outcomes following several novel high-dose regimens with autologous stem cell rescue for the treatment of epithelial carcinoma of the ovary. Proc ASCO 16: 376a, 1997.

Saez R, **Perkins J**, Goldstein S, et al. Multivariate analysis of pre and post transplant factors related to outcome in 65 consecutive allogeneic transplant patients receiving cyclosporine/methotrexate as graft versus host disease prophylaxis Exp Hematol 25:821, 1997.

Fields KK, Fraraccio M, Trudeau WL, **Perkins JB**, and Kronish, LE. Tumor contamination of peripheral blood stem cell products in patients with metastatic breast cancer undergoing high dose chemotherapy and autologous stem cell transplant: Clinical outcomes. Blood 90:402b, 1997.

Ballester O, Moscinski L, Lyman G, **Perkins J**, Elfenbein G, Goldstein S, Sullivan D, Saez R, Fields K. Plasmoblastic morphology and proliferative compartment as prognostic indicators for multiple myeloma patients treated with high-dose therapy and autologous stem cell transplants. Proceedings of ASCO, 1998.

Fields, KK **Perkins J**, Goldstein SC, Elfenbein GJ, Saez RA, Sullivan DM, Partyka JB, Kronish LC. High dose chemotherapy for the treatment of high risk early stage breast cancer Analysis of risk factors Diagnostic und Therapie des Mammakarzinoms State of the Art. Untch M, Konecny G, Sittek H, Kessler M, Reiser M, Hepp H, Eds) W. Zuckeswerdt, Verlag, Muchen, 1998.

Elfenbein GJ, Partyka J, Saez R, Goldstein S, Fields KK, **Perkins J**, and Janssen WE. Determination of risk factors that affect engraftment after allogeneic bone marrow transplantation. Exp Hematol 26: 692, 1998.

Fields KK, **Perkins JB**, Partyka JS, Sullivan DM, Goldstein SC. High Dose Thiotepa, Novantrone-R, and Taxol-R (TNT) Followed By Autologous Stem Cell Transplant: Results of a Phase II Study in Women with Chemoresponsive Metastatic Breast Cancer. Proc ASCO. 18:182, 1999.

Salim M, Fields KK, Partyka JS, **Perkins JB**, Smilee R. Delayed Administration of G-CSF Following High Dose Chemotherapy (HDCT) and Autologous Peripheral Blood Stem Cell Transplant (PBSCT) Collected After Chemotherapy and G-CSF or G-CSF Alone Does Not Delay Granulocyte Recovery. Proc ASCO. 18:172, 1999.

WE Janssen, RC Smilee, J Partyka, **JB Perkins**, KK Fields. Granulocyte and Platelet Engraftment Following Infusion of Stem Cells Collected from Patients who Mobilize Peripheral Blood Stem Cells (PBSC) Poorly. Presented at: ISHAGE '99. Electronically submitted, April, 1999.

Sullivan DM, Partyka JS, Hernandez AN, Trudeau WL, Fields K, Goldstein SC, **Perkins JB**, Maddox BL, Keller RK. A Phase I/II Study of Intensive-Dose Topotecan (TPT), Ifosfamide (IFOS)/Mesna and

Etoposide (TIME) Followed by Autologous Stem Cell Rescue in Refractory Malignancies. Proc ASCO. 18:171, 1999.

Fields, KK, Sullivan, DM, **Perkins, JB**, Partyka, JS and McIsaacs, C. A Phase I Dose Escalation and Pharmacokinetic Study of Topotecan, Ifosfamide (with Mesna) and Etoposide (Time) with Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Chemorefractory Metastatic Breast Cancer. Presented at 10th International Symposium on Autologous Blood and Marrow Transplantation, July 2000, Electronically submitted, June 2000.

Goldstein SC, **Perkins J**, Janssen WE, Field T, Partyka J, Loughran T, Djulbegovic B, Sullivan D, Reimer D, Fields K. A prospective, comparative trial of allogeneic versus autologous stem cell transplantation for high risk lymphoma: Interim analysis. ASH Annual Meeting 2000.

Sullivan, D., Partyka, J., Dalton, W., Fields, K., Field, T., Goldstein, S., **Perkins, J.**, Janssen, W., Valkov, N., Gump, J., Turner, J., McIsaac, C. A Phase I/II Study of High-Dose Melphalan +Topotecan+VP-16 Phosphate (MTV) Followed by Autologous Stem Cell Rescue in Multiple Myeloma. Proc ASCO 2001 abstract 53

Sullivan, D.M., Partyka, J., Dalton, W., Djulbegovic, B., Fields, K., Field, T., Goldstein, S., **Perkins, J.**, Janssen, W., Valkov, N., Gump, J., Turner, J., and McIsaac, C. A Phase I/II Study of High-dose Melphalan + Topotecan + VP-16 Phosphate (MTV) Followed by Autologous Stem Cell Rescue in Multiple Myeloma. Proc. ASCO, 53, 2001.

Goldstein SC, **Perkins J**, Janssen WE, Field T, Smith C, Loughran T, Sullivan D, Fields K. A prospective, comparative trial of high dose therapy followed by allogeneic versus autologous stem cell transplantation in 100 patients with high risk lymphoma. American Society for Blood and Marrow Transplantation Annual Meeting, February 2002 abstract #58

Goldstein SC, **Perkins J**, Field T, Janssen W, Alsina M, Sullivan D, Fields K. Smith C. Myeloablative conditioning with TBI/VP16 with allogeneic stem cell transplantation for multiple myeloma: High response rate and prolonged progression free survival. Biology of Blood and Marrow Transplantation February 2003, Supplement • Volume 9 • Number 2

Ayala E, Greene J, Sandin R, **Perkins J**, Field T, Tate C, Goldstein S. Oral valganciclovir is safe and effective as preemptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation February 2004, Supplement • Volume 10 • Number 1

Field T, **Perkins J**, Alsina M, Ayala E, Fancher K, Janssen W, Perez L, Sullivan D, Tate C, and Anasetti C. Targeted Intravenous Busulfan Combined with Fludarabine (tBuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Stem Cell Transplant: Early Results of Low Treatment Related Mortality. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 1759

Field T, **Perkins J**, Alsina M, Ayala E, Fancher K, Janssen W, Perez L, Sullivan D, Tate C, Anasetti C. Low treatment related mortality and improved survival in allogeneic peripheral blood stem cell transplant: Targeted intravenous Busulfan combined with Fludarabine (tBuFlu) as conditioning regimen Biology of Blood and Marrow Transplantation February 2006, Supplement 1 • Volume 12 • Number 2 •

Field T, **Perkins J**, Alsina M, Ayala E, Fancher K, Fernandez H, Garrett D, Janssen W, Kharfan-Dabaja M, Perez L, Sullivan D, Tate C, and Anasetti C. Busulfan Area-under-the-Curve Finding Study within a Busulfan/Fludarabine (BuFlu) Conditioning Regimen before Allogeneic Hematopoietic

Cell Transplantation (HCT). Blood (ASH Annual Meeting Abstracts), Nov 2006

- T. Field, **J. Perkins**, M. Alsina, E. Ayala, H.F. Fernandez, W. Janssen, M. Kharfan-Dabaja, J. Lancet, L. Perez, D. Sullivan, A List, C. Anasetti, Pre-Transplant 6-Azacitidine (Vidaza®) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients With Myelodysplastic Syndrome (MDS). Blood 2006; 108 (11): 1046a (abst. #3664-poster presentation).
- Kharfan-Dabaja M, Tate C, **Perkins J**, Fernandez H, Field T, Ayala E, Perez L, Raychaudhuri J, Alsina M, Sullivan D, Brand L, Poling W, Anasetti C. Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies. Blood (ASH Annual Meeting Abstracts), Nov 2007
- Field T, Alsina M, Ayala E, Fernandez H, Janssen W, Karfan-Dabaja M, Lancet J, Melchert M, Raychaudhuri J, Sullivan D, List A, Anasetti C, Poling W, **Perkins J** Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine. Blood (ASH Annual Meeting Abstracts), Nov 2007
- Sullivan D, Alsina M, Anasetti C, Field T, Kharfan-Dabaja M, Fernandez H, Dalton W, Ayala E, Raychaudhuri J, Perez L, **Perkins J**, Schell M, McIsaac C, Maddox B, Gump J, Lush R, Frudakis, T. Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts), Nov 2007
- Field T, Alsina M, Ayala E, Fernandez HF, Janssen W, Kharfan-Dabaja M, Lancet J, Melchert M, Raychaudhuri J, Sullivan D, List A, Anasetti C, Poling W, and **Perkins J**. Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine (Vidaza). Blood 2007; 110 (11): 339b (abs#5035)
- Alekshun TJ, McIsaacs-Simonelli C, Kharfan-Dabaja M, Dalton W, Djulbegovic B, Fernandez, Sullivan DM, Ayala E, Field TL, Garrett D, Janssen WE, Maddox B, Perez L, Pountney S, Kettner D, **Perkins J**, Anasetti C, Alsina M. Phase I study of Bortezomib (BTZ) Followed by High-Dose Melphalan, (HD Mel) and Bortezomib as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants in Patients with Primary Refractory Multiple Myeloma and Plasma Cell Leukemia Blood 2007; 110 (11): 365b (abs#5131)
- Sullivan D, Alsina M, Anasetti C, Field T, Kharfan-Dabaja M, Fernandez H, Dalton W, Ayala E, Raychaudhuri J, Perez L, **Perkins J**, Schell M, McIsaac C, Maddox B, Gump J, Lush R, Frudakis T. Phase I/II trial of high dose Melphalan (M) and Topotecan (T) followed by autologous stem cell rescue in patients ≤ 60 and > 60 years of age with multiple myeloma (MM). Blood 2007; 110 (11): 286a (abs# 943- poster presentation)
- Kharfan-Dabaja MA, Tate C, **Perkins J**, Fernandez HF, Field T, Ayala E, Perez L, Raychaudhuri J, Alsina M, Brand L, Poling W and Anasetti C. Administration of rituximab is feasible and does not affect engraftment of allograft recipients with advanced CD20+ malignancies. Blood 2007; 110 (11): 885a (abs# 3016- poster presentation)
- Alsina M, Alekshun T, McIsaac-Simonelli C, Kharfan-Dabaja M, Dalton W, Djulbegovic B, Fernandez H, Sullivan DM, Ayala E, Field T, Garrett D, Janssen WE, Maddox B, Perez LE, Kettner D, **Perkins J**, Raychaudhuri J, Anasetti C. Phase I study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD- Mel) and BTZ as conditioning regimen for Tandem Peripheral Blood Stem Cell

Transplants (Tan PSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL). Biol Blood Marrow Transplant 2008; 14 (2, suppl 2): 68 (abs# 184-poster presentation).

Kharfan-Dabaja MA, Tate C, **Perkins J**, Fernandez HF, Field T, Ayala E, Perez L, Raychaudhuri J, Alsina M, Ochoa-Bayona L, Sullivan D, Brand L, Poling W, Anasetti C. Rituximab is Feasible to Administer to Allograft Recipients with Advanced CD20+ Malignancies and Does Not Affect Timely Hematopoietic Engraftment. Biol Blood Marrow Transplant 2008; 14 (2, suppl 2): 121 (abs# 330-poster presentation).

Paoletti C, Balducci L, Boler I, Popa-McKiver M, Extermann M, Raychaudhuri J, Anasetti C, Fernandez H, Sullivan D, Dalton W, Field T, Ayala E, Kharfan-Dabaja M, Perez L, **Perkins J**, Janssen W, Harris J, Schell MJ, Kapoor R, Alsina M, Ochoa-Bayona JL. Age remains the strongest independent prognostic factor in patients with multiple myeloma undergoing autologous stem cell transplantation: Moffitt Cancer Center experience. Blood 2008; 112: 4435 (abstract publication)

M.A. Kharfan-Dabaja, C. Tate, **J. Perkins**, T. Field, H.F. Fernandez, M. Alsina, E. Ayala, J. Raychaudhuri, L. Perez, J. L. Ochoa-Bayona, L. Brand, J. Pinilla-Ibarz, E. Sotomayor, D. Sullivan, C. Anasetti. Administration of Rituximab 375 mg/m² on Days +1 and +8 After Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Malignancies. Submitted to Am Soc Hematol, 2008. Blood 2008; 112: 4323 (abstract publication)

M.A. Kharfan-Dabaja, J. C. Chavez, E. I. Fernandez-Vertiz, D. Yu, W. Zhu, **J. Perkins**, T. Field, E. Ayala, H.F. Fernandez, M. Alsina, L. Perez, J. Raychaudhuri, J. L. Ochoa-Bayona, L. Brand, D. Sullivan, C. Anasetti. Hypoalbuminemia (<3.0 g/dl) and Poor Karnofsky performance Score (<80) at Day 90 Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) are Independent Predictors of Worse Non-relapse Survival (NRS) and Overall Survival (OS): A Multivariable Analysis Approach of Various Clinical, Laboratory, and Pharmacologic Parameters. Blood 2008; 112: 4329 (abstract publication)

Gergis, U., Markey, K., Greene, J., Kharfan-Dabaja, M., Wetzstein, G., Anasetti, C., **Perkins, J.** Voriconazole Is Effective Prophylaxis for Aspergillus Invasive Fungal Infection (IFI) in Patients Receiving Glucocorticosteroid Therapy for GVHD after Allogeneic Transplantation Biology of Blood and Marrow Transplantation February 2008, Supplement • Volume 12 • Number 2

Perkins, J., Alsina, M, Anasetti, C, Ayala, E, Fernandez, H, Kharfan-Dabaja, M, Ochoa-Bayona, L, Perez, L, Raychaudhuri, J, Sullivan, D, Kim, J, Schell, J and Field, T. A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival. Blood (ASH Annual Meeting Abstracts; Poster Presentation), Nov 2008

J Perkins, M Alsina, E Ayala, K Fancher, H Fernandez, M Kharfan-Dabaja, L Ochoa-Bayona, L Perez, J Raychaudhuri, D Sullivan, C Tate, T Field. Safety Profile of Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant. Accepted for presentation (poster presentation) at the ASBMT 2009 (Biol Blood Marrow Transplant 2009; 15 (2 suppl 2. abst # 295, pp. 107).

Paoletti C, Balducci L, Alsina M, Boler I, Popa MA, Extermann M, Lara-Rivera S, Raychaudhuri J, Anasetti C, Fernandez H, Sullivan D, Dalton WS, Field T, Ayala E, Kharfan-Dabaja M, Perez L, **Perkins J**, Janssen W, Harris J, Schell MJ, Kim J, Ochoa-Bayona JL. Autologous Stem cell transplantation (ASCT) in patients aged ≥ 65 years with multiple myeloma: Moffitt Cancer

Center experience. Accepted for presentation (poster presentation) at the ASBMT 2009 (Biol Blood Marrow Transplant 2009; 15 (2 suppl 2. abst # 182, pp. 68).

- HF Fernandez, **J Perkins**, T Field, M Alsina, E Ayala, M. Kharfan-Dabaja, J Leonel Ochoa, L Perez, J Raychaudhuri, and C Anasetti. Tolerability and Outcomes of a Targeted Intravenous Busulfan and Fludarabine (t-Bu/Flu) Conditioning Regimen for the Treatment *de novo* and Secondary Acute Myeloid Leukemia (AML). Accepted for presentation (poster presentation) at the ASBMT 2009 (Biol Blood Marrow Transplant 2009; 15 (2 suppl 2. abst # 167, pp. 62-63).
- C Anasetti, S Santarone, M Alsina, E Ayala, T Field, M. Kharfan-Dabaja, L Ochoa, L Perez, **J Perkins**, J Raychaudhuri, D Sullivan, MD¹ and H Fernandez. Safety and efficacy of fludarabine and PK-targeted intravenous busulfan before allografting for adult ALL. Accepted for presentation (poster presentation) at the ASBMT 2009 (Biol Blood Marrow Transplant 2009; 15 (2 suppl 2. abst # 172, pp. 64)
- MA. Kharfan-Dabaja, JC. Chavez, E. I Fernandez-Vertiz, D Yu, W Zhu, **J Perkins**, T Field, E Ayala, HF. Fernandez, M Alsina, L Perez, J Raychaudhuri, J. L Ochoa-Bayona, L Brand, D Sullivan, and C Anasetti. Hypoalbuminemia (< 3.0 g/dl) and Poor Karnofsky Performance (KPS<80) at day +90 are Independent Predictors of Worse Non-Relapse Survival (NRS) and Overall Survival (OS) in Adult Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients: Results of a Multivariable Analysis. Accepted for presentation (**oral presentation**) at the ASBMT 2009 (Biol Blood Marrow Transplant 2009; 15 (2, suppl 2. abs #11, pp6).
- Pidala JA, Hoda D, Salgado-Vila N, Kim J, **Perkins J**, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona J, Raychaudhuri J, Alsina M, Greene JN, Janssen WE, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease. Poster Presentation, 2009 ASH Annual Meeting, Abstract 2235
- Pidala J, Kim J, Anasetti C, Alsina M, Ayala E, Field T, Kharfan-Dabaja MA, Ochoa L, Perez L, **Perkins J**, Tomblyn M and Fernandez HF. Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia. Poster Presentation, 2009 ASH Annual Meeting, Abstract 2290
- J Perkins**, J Kim, C Anasetti, MA Kharfan-Dabaja, E Ayala, L Perez, H Fernandez, K Fancher, C Tate, and T Field, MD Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes. Poster Presentation, 2009 ASH Annual Meeting, Abstract 3347
- A McBride, K Fancher, J Kim, D Davis, M Conwell, T Field, C Anasetti, and **J Perkins**. Pretransplant Factors That Influence Intravenous Busulfan Kinetics in Adult Patients Poster Presentation, 2009 ASH Annual Meeting, Abstract 3350.
- T Field, **J Perkins**, MA Kharfan-Dabaja, HF Fernandez, L Perez, JL Ochoa-Bayona, JE Lancet, RS Komrokji, M Alsina, E Ayala, AF List and C Anasetti MD. Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes. Poster Presentation, 2009 ASH Annual Meeting, Abstract 3383
- Field, T.L., **Perkins, J.**, Kim, J., Kharfan-Dabaja, M.A., Fernandez, H.F., Perez, L., Lancet, J., Komrokji, R.S., Ochoa-Bayona, L., Alsina, M., List, A., Anasetti, C. Evaluation Of Patients With

Myelodysplastic Syndrome (MDS) Up To Age Seventy-Five, Referred For Allogeneic Hematopoietic Cell Transplant (HCT) Including Donor Availability And HCT Outcomes. Oral Presentation, 2010 ASBMT Annual Meeting, Abstract 11.

Perkins, J., Bookout, R., Shapiro, J., Alsina, M., Ayala, E., Field, T.L., Kharfan-Dabaja, M.A., Perez, L.E., Ochoa-Bayona, J.L., Tomblyn, M., Daily, K., Elstner, C., Anasetti, C., Fernandez, H.F. Retrospective Comparison Of Secondary Mobilization Strategies In Candidates For Autologous Hematopoietic Cell Transplantation With A Focus On Resource Utilization: Plerixafor + G-CSf Versus Other Regimens. Poster Presentation, 2010 ASBMT Annual Meeting, Abstract 118.

Shapiro, J., Bookout, R., **Perkins, J.**, Ayala, E., Alsina, M., Field, T., Kharfan-Dadaja, M.A., Perez, L.E., Ochoa-Bayona, J.L., Tomblyn, M., LaFave, D., Anasetti, C., Fernandez, H.F. Primary Plerixafor Mobilization In Autologous Hematopoietic Cell Transplant Candidates At High Risk For Mobilization Failure. Poster Presentation, 2010 ASBMT Annual Meeting, Abstract 131.

Pidala, J., Kim, J., Alsina, M., Ayala, E., Field, T., Fernandez, H., Kharfan-Dabaja, M., Ochoa, L., Perez, L., **Perkins, J.**, Tomblyn, M., Anasetti, C. Dysglycemia Following Glucocorticoid Therapy For Acute Graft Vs. Host Disease Adversely Affects Transplantation Outcomes. Poster Presentation, 2010 ASBMT Annual Meeting, Abstract 324.

Kharfan-Dabaja, M.A., **Perkins, J.**, Cortes, R., Brand, L., Fernandez, H.F., Ochoa-Bayona, J.L., Field, T., Perez, L., McIsaac, C., Maddox, B., Ayala, E., Komrokji, R., Pinilla-Ibarz, J., Sotomayor, E., Tomblyn, M., Anasetti, C. A Novel Reduced Toxicity Preparative Regimen For Hematopoietic Cell Allografting Combining Pentostatin (Nipent®) And Targeted Doses Of Intravenous Busulfan (Busulfex®) With Or Without Rituximab (Pb±R) Using Cd4-Guided Immune Suppression: Preliminary Results Of An Ongoing Prospective Trial Poster Presentation, 2010 ASBMT Annual Meeting, Abstract 332

Roman-Diaz, J.L., Pidala, J., Nishihori, T., **Perkins, J.**, Tate, C., Ochoa, J., Ayala, E., Fernandez, H.F., Anasetti, C., Kharfan-Dabaja, M.A. Targeted Iv Busulfan And Fludarabine Followed By Post-Allogeneic Hematopoietic Cell Transplantation Rituximab Demonstrate Encouraging Activity In High Risk Cd20+ Positive Lymphoid Malignancies Without Increased Infectious Complications. Poster Presentation, 2010 ASBMT Annual Meeting, Abstract 356

Nishihori, T., **Perkins, J.**, Pidala, J., Roman, J., Kim, J., Fernandez, H., Anasetti, C., Kharfan-Dabaja, M.A. Allogeneic Hematopoietic Stem Cell Transplantation In Myelofibrosis: Single Center Experience. Poster Presentation, 2010 ASBMT Annual Meeting, Abstract 366

Teresa Field, **Janelle Perkins**, Taiga Nishihori, Joseph Pidala, Hugo F. Fernandez, Marcie Tomblyn, Mohamed Kharfan-Dabaja, Lia Perez, Rami S. Komrokji, Jeffrey E. Lancet, Jongphil Kim, Ernesto Ayala, Melissa Alsina, Jose-Leonel ochoa-Bayona, Alan F. List, and Claudio Anasetti Prospective Trial of Pre-Transplant 5-Azacididine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML. Blood (ASH Annual Meeting Abstracts; poster presentation), Nov 2010; 116: 1333.

Janelle Perkins, Teresa Field, Jongphil Kim, Hugo F. Fernandez, Lia Perez, Ernesto Ayala, Mohamed Kharfan-Dabaja, Marcie Tomblyn, Daniel Sullivan, and Claudio Anasetti Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Blood (ASH Annual Meeting Abstracts; poster presentation), Nov 2010; 116: 3499.

Teresa Field, **Janelle Perkins**, Taiga Nishihori, Joseph Pidala, Hugo F. Fernandez, Marcie Tomblyn, Mohamed Kharfan-Dabaja, Lia Perez, Jeffrey E. Lancet, Rami S. Komrokji, Jose-Leonel ochoa-Bayona, Melissa Alsina, Ernesto Ayala, Jongphil Kim, Alan F. List, and Claudio Anasetti. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic

Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor. Blood (ASH Annual Meeting Abstracts; poster presentation), Nov 2010; 116: 2381.

Janelle Perkins, Teresa Field, Jongphil Kim, Hugo F. Fernandez, Lia Perez, Ernesto Ayala, Mohamed Kharfan-Dabaja, Marcie Tomblyn, Daniel Sullivan, and Claudio Anasetti. Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. Volume 17, Issue 2, Supplement , Page S302, February 2011 ASBMT Annual Meeting; poster presentation

J. Pidala M. Tomblyn T. Nishihori **J. Perkins** T. Field E. Ayala M. Alsina L. Ochoa F. Locke L. Perez H. Fernandez C. Anasetti Sirolimus Induces Complete Remission of Acute Graft-Versus-Host Disease Without Systemic Glucocorticoids. Biology of Blood and Marrow Transplantation Volume 17, Issue 2, Supplement , Page S332, February 2011 ASBMT Annual Meeting, poster presentation.

J. Pidala, M. Tomblyn, T. Nishihori, **J. Perkins**, T. Field, E. Ayala, R. Bookout, M. Conwell, L. Perez, L. Ochoa, M. Alsina, J. Shapiro, C. Tate, F. Locke, H. Fernandez, C. Anasetti. ATG for the Prevention of Severe Acute Graft-Versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation Volume 17, Issue 2, Supplement , Page S338, February 2011 ASBMT Annual Meeting, poster presentation.

T.L. Field, **J. Perkins**, T. Nishihori, J. Pidala, M. Tomblyn, H. Fernandez, L. Perez, M.A. Kharfan-Dabaja, R.S. Komrokji, J. Lancet, E. Ayala, M. Alsina, L. Ochoa, J. Kim, A. List, C. Anasetti. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: Comparison of Survival in Patients With an Available Donor Compared to Patients Without a Donor in Patients Up to Age 75. Biology of Blood and Marrow Transplantation Vol. 17, Issue 2, Supplement, Page S300 February 2011 ASBMT Annual Meeting, poster presentation.

J. Shapiro, **J. Perkins**, R. Bookout, E. Ayala, H. Fernandez, W. Janssen, C. Anasetti. Plerixafor Use in Autologous Hematopoietic Cell Transplant Candidates at High Risk for Mobilization Failure. Biology of Blood and Marrow Transplantation Vol. 17, Issue 2, Supplement, Page S207 ASBMT Annual Meeting, poster presentation

T.L. Field, **J. Perkins**, J. Pidala, T. Nishihori, M. Tomblyn, H. Fernandez, L. Perez, M.A. Karfan-Dabaja, R. Komrokji, J. Lancet, E. Ayala, M. Alsina, L. Ochoa, J. Kim, A. List, C. Anasetti. Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML. Biology of Blood and Marrow Transplantation Vol. 17, Issue 2, Supplement, Page S312, ASBMT Annual Meeting, poster presentation

Joseph Pidala, Jongphil Kim, Mohamed A. Kharfan-Dabaja, Taiga Nishihori, Teresa Field, **Janelle Perkins**, Lia Perez, Hugo Fernandez, Claudio Anasetti. Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes. Biology of Blood and Marrow Transplantation Vol. 17, Issue 2, Pages 239-248, ASBMT Annual Meeting, poster presentation

Gang Han, Ji-Hyun Lee, and **Janelle Perkins**. A Parametric Comparison for Survival Data with Multiple Events and Failure Changes in Cancer Research. Eastern North American Region/International Biometric Society Meeting (ENAR), Miami, FL March 22, 2011

- R.S. Komrokji, E Alrawi, N Al Ali, J Perkins, T Field, PK Epling-Burnette, L Zhang, J.E. Lancet, and A.F. List. Outcome of Azacitidine Treatment in Patients with Therapy Related Myelodysplastic Syndrome; MDS Symposium
- Kharfan-Dabaja MA, Anasetti C, Luis, N Brand L, **Perkins J**, Fernandez HF., Ochoa-Bayona JL, Nishihori T, Perez LE, Ayala E, Pinilla-Ibarz J, Sokol L, Pidala J, Locke FL, Sotomayor EM., Field T, and Tomblyn M. Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression. Blood (ASH Annual Meeting Abstracts; poster presentation), Nov 2011; 118: 3022.
- Shapiro J, **Perkins J**, Bookout R, Tombleson R, Ayala E, Janssen WE., Anasetti C, and Fernandez HF. Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates Blood (ASH Annual Meeting Abstracts; poster presentation), Nov 2011; 118: 4060.
- Pidala J, Kim J, Jim H, Fernandez HF., Tomblyn M, Kharfan-Dabaja MA, Betts BC., Nishihori T, Xu M, Janssen WE., Locke FL, Ayala E, Perez L, **Perkins J**, Field T, Ochoa L, Alsina M, and Anasetti C. Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. Blood (ASH Annual Meeting Abstracts; oral presentation), Nov 2011; 118: 323
- Komrokji RS., Ali NHA, Alrawi E, Padron E, **Perkins J**, Field T, Lance JE. and List AF. Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome. Blood (ASH Annual Meeting Abstracts; poster presentation), Nov 2011; 118: 1712
- Kunter GM, **Perkins J**, Perez L, Pidala J, Field T, Tomblyn M, Fernandez HF, and Anasetti C. Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission. Blood (ASH Annual Meeting Abstracts; oral presentation), Nov 2011; 118: 891.
- Figuerola J., **Perkins J.**, C Anasetti., Tomblyn M., Field T., Fernandez H., Ochoa J., Perez L., Alsina M. Locke F., Nishihori T., Pidala J., Ayala E.. Myeloablative Doses of Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation in Non-Hodgkin'S Lymphoma Biology of Blood and Marrow Transplantation 2012 Vol. 18, Issue 2, Supplement, Page S297
- CruzChacon A.M., **Perkins J.B.**, Pidala J.A., Kim J., Yue B., Field T., Anasetti C.. Impact of a Lower Busulfan Area Under the Concentration-Time Curve (AUC) Dosing Target on Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes. Biology of Blood and Marrow Transplantation 2012 Vol. 18, Issue 2, Supplement, Page S340
- Kharfan-Dabaja M.A., Mhaskar R., Pidala,J.A. **Perkins J.B.**, B Djulbegovic., Kumar A. Comparison of Mycophenolate Mofetil (MMF) Versus Methotrexate (MTX) for Prevention of Acute Graft-Versus-Host Disease: Results of a Meta-Analysis. Biology of Blood and Marrow Transplantation 2012 Vol. 18, Issue 2, Supplement, Pages S358-S359
- Field,T. **Perkins J.**, Nishori,T. Pidala J., Fernandez H.F., Tomblyn M., Kharfan-Dabaja M., Perez L., Komrokji R.S., Lancet J., Kim J., Ayala E., Alsina M., Ochoa-Bayona J.-L., . Locke F, Betts B., List A., Anasetti C.. Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML. Biology of Blood and

Marrow Transplantation 2012 Vol. 18, Issue 2, Supplement, Page S338

Pidala J., Kim J., M Schell., Hillgruber R., Nye V, Ayala E, M Alsina., Betts B., R Bookout., Fernandez H.F., T Field., F Locke.L., T Nishihori., Ochoa J.L., Perez L., **Perkins J.**, Shapiro J., C Tate., Tomblyn M., C Anasetti.. Effectiveness of Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: Results of a Donor Vs. No Donor Analysis. Biology of Blood and Marrow Transplantation 2012 Vol. 18, Issue 2, Supplement, Pages S267-S268

Invited Talks

"Biologic Response Modifiers in Hematology"; Oral Presentation; American Society of Hospital Pharmacists Midyear Clinical Meeting 1990; Las Vegas, NV

"Ondansetron-What We Know One Year Later"; Oral Presentation; Florida Society of Hospital Pharmacists, Annual Meeting 1992; Orlando, FL

"Management of the In and Out-patient Receiving Aggressive Chemotherapy"; Oral Presentation; Eighth Annual Pharmacy Seminar - Modulation of Serotonin and It's Global Impact on Health Care, 1993; Tampa, FL

"New Directions in Bone Marrow Transplantation: Impact of Interleukins, Colony Stimulating Factors, and Combination Cytokine Therapy." Oral Presentation; American Society of Hospital Pharmacists Annual Meeting, 1993; Denver, CO

"Bone Marrow Transplantation" Oral presentation at the American Association of Pharmacy Technicians Annual Convention, 1993; St. Petersburg, FL

"Application of Pharmacist Impact on Improving Patient Outcomes: Women's Cancers" Oral Presentation at the Florida Society of Hospital Pharmacists' Midyear Meeting, 1994; Ft. Lauderdale, FL

"Hematopoietic Growth Factors" Oral Presentation, VHA Central Pharmacy Meeting, 1995; Columbus, OH

"Novel High Dose Regimens for the Treatment of Breast Cancer" Oral Presentation, 8th International Symposium on Autologous Marrow and Blood Transplantation, 1996, Arlington, TX

"Use of 5HT₃ Antagonist to Prevent Emesis After High Dose Chemotherapy" Platform Presentation, Smith Kline Beecham Consultant's Meeting, 1998, St Petersburg, FL

"Breast Cancer Update" Oral Presentation to Pasco-Hernando Pharmacy Association, 1999, New Port Richey, FL

"The Role of Nonmyeloablative Transplants and Donor Lymphocyte Infusions in the Treatment of Malignancies" American College of Clinical Pharmacy, 2002, Savannah, GA

"Pharmaceuticals Used in Blood and Marrow Transplantation" United Resource Network Case Managers Conference; presented biannually from 10/02-4/05

“Patient’s Decision Making Process Regarding Participation in Phase I Oncology Research” 7th USF Symposium on Bioethics, 2007, Tampa, FL

“Developing Informed Consent Documents for Clinical Research: Where Art Meets Science” American College of Clinical Pharmacy Annual Meeting, 2009-2013

“College of Pharmacy Investigational Drug Pharmacy: Operations and Offerings” USF College of Pharmacy Education and Research Forum, 2013, Tampa, FL

Research Support

Current Funding

PI:	Janelle Perkins, PharmD
Type of study:	Investigator-initiated, pharmaceutically supported retrospective review
Dates:	Contract pending
Source:	Otsuka
Title:	Single Institution Retrospective Analysis Of Myeloablative Doses Busulfan And Fludarabine As Conditioning For Allogeneic Stem Cell Transplantation In Non Hodgkin’s Lymphoma
Role in the Study:	PI
Subjects enrolled:	79
Amount of Award:	\$43, 290

Completed Funding/Clinical Trials:

- 1)

Account #:	6302-EM0303
PI or Co-PI:	Daniel Sullivan, MD
Type of study:	Investigator-initiated, pharmaceutically supported clinical trial
Dates:	2001 – 2011
Source:	Glaxo SmithKline
Title:	A Phase I/II Study of Intensive-Dose Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients with Multiple Myeloma (MCC12733)
Role in the Study:	Co-investigator (provide ongoing input with respect to protocol design and implementation; provide data analysis; manuscript preparation)
Subjects enrolled:	150
Amount of Award:	\$3500/subject

- 2)

Account #:	84-15-55-01-01
PI or Co-PI:	Janelle Perkins, PharmD (Co-PI, Teresa Field, MD, Ph.D)
Type of study:	Investigator-initiated, pharmaceutically supported clinical trial
Dates:	2005-2009
Source:	PDL Pharma
Title:	Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) (MCC 14178)

- % Effort, if applicable: 20%
- Role in the Study: Co-PI
- Subjects enrolled: 79
- Amount of Award: \$200,000
- 3) PI or Co-PI: Janelle Perkins, Pharm.D (Co-PI Teresa Field, MD, Ph.D)
 Type of study: Investigator-initiated, pharmaceutically supported clinical trial
 Dates: 2005-2010
 Source: Astellas Pharma US, Inc
 Title: Tacrolimus and Methotrexate versus Tacrolimus and Mycophenolate Mofetil as Acute Graft versus Host Disease Prophylaxis in Recipients of Allogeneic Hematopoietic Stem Cell Transplants (MCC 14418)

 Role in the Study: Co-PI
 Subjects enrolled: 95
 Amount of Award: \$2736.50/subject
 - 4) Account #: 84-15-55-01-01
 PI or Co-PI: Janelle Perkins, PharmD (Co-PI, Teresa Field, MD, Ph.D)
 Type of study: Investigator-initiated, pharmaceutically supported retrospective chart review

 Dates: 2006-2009
 Source: PDL Pharma
 Title: A Retrospective Analysis Evaluating Prognostic Indicators for Posttransplant Outcomes in Patients Receiving Busulfan/Fludarabine (BuFlu) Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) (MCC15268)

 Role in the Study: PI
 Subjects enrolled: 195
 Amount of award: \$73,820
 - 5) Account #: 84-15103-99-01
 PI or Co-PI: Janelle Perkins, PharmD
 Type of study: Investigator-initiated, pharmaceutically supported retrospective chart review

 Dates: 2007-2009
 Source: Pfizer
 Title: A Retrospective Analysis Evaluating the Incidence of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Cells in the Era of Voriconazole Therapy (MCC15209)

 Role in the Study: PI
 Subjects enrolled: 169
 Amount of award: \$50,000
 - 6) PI or Co-PI: Janelle Perkins, PharmD (Co-PI, Teresa Field, MD, Ph.D)
 Type of study: Investigator-initiated, pharmaceutically supported clinical trial
 Dates: 2008-2010
 Source: Pharmion
 Title: A Pilot Study Of Pretransplant 5-Azacididine (Vidaza®) In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplantation (MCC15158)

Role in the Study:	Co-PI (provide ongoing input with respect to protocol design and implementation; provide data analysis; manuscript preparation)
Subjects enrolled:	23
Amount of award:	\$4712.50/subject
7) PI or Co-PI	Janelle Perkins, PharmD (Co-PI, Hugo Fernandez, MD)
Type of study	Investigator-initiated, pharmaceutically supported retrospective chart review
Dates:	2009-2010
Source:	Genzyme
Title:	Retrospective Comparison of Secondary Mobilization Strategies in Candidates for Autologous Hematopoietic Cell Transplant (HCT)
Role in the Study:	Co-PI
Subjects enrolled:	100
Amount of award:	\$100,000